drugset / Trial / NCT04965675
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
RandomizedParallel-groupDouble-blindTreatment
Summary
To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.
Timeline
- Start
- 2021-06-30
- Primary completion
- 2026-09-05
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptinezumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Eptinezumab | Monoclonal antibody | 300 mg | Intravenous |
Indications
No indication recorded.